文献速递肝病

分泌素通过恢复分泌过程减轻晚期原发性胆汁性胆管炎的胆管和肝损伤

Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
PubMed 文献 · J Hepatol · 2022-08-18

在晚期原发性胆汁性胆管炎(PBC)小鼠模型和人样本中,胆道分泌素/分泌素受体信号及胆汁碳酸氢盐水平降低。分泌素治疗1或8周可减少胆管丢失、胆管反应、炎症和纤维化,恢复胆管-毛细胆管连接和碳酸氢盐伞,并促进成熟胆管细胞标志物Agr2及黏蛋白1表达。作者认为分泌素治疗可能对晚期PBC患者有益。

要点

  • 晚期PBC小鼠模型和人样本中胆道分泌素/分泌素受体/CFTR/AE2表达及胆汁碳酸氢盐水平降低。
  • 分泌素治疗减少晚期PBC模型的胆管丢失、胆管反应、炎症和纤维化,并恢复胆管-毛细胆管连接和碳酸氢盐伞。
  • 分泌素促进成熟胆管细胞标志物Agr2表达和黏蛋白1水平,作者认为可能对晚期PBC患者有益。

核心结论

  • 晚期PBC中分泌素/分泌素受体信号丢失导致碳酸氢盐伞缺陷和Agr2介导的黏蛋白产生减少。
  • 分泌素通过增强成熟胆管细胞表型和胆管生长恢复胆管细胞分泌过程及胆管-毛细胆管连接形成。
  • 分泌素治疗可能对晚期PBC患者有益。

研究设计与样本

  • 在32周龄雌性和雄性野生型及显性负性转化生长因子β受体II(晚期PBC模型)小鼠中,给予分泌素治疗1或8周。
  • 对小鼠模型分离的胆管细胞进行批量RNA测序。
  • 评估晚期PBC小鼠模型及人样本中分泌素/分泌素受体信号与胆道分泌过程。

主要发现

  • 晚期PBC小鼠模型和人样本中胆道分泌素/分泌素受体/CFTR/AE2表达及胆汁碳酸氢盐水平降低。
  • 分泌素治疗减少晚期PBC模型的胆管丢失、胆管反应、炎症和纤维化。
  • 分泌素降低肝脏胆汁酸水平、改变胆汁酸组成,并恢复胆管-毛细胆管连接和碳酸氢盐伞。
  • RNA测序显示分泌素促进成熟上皮标志物表达,特别是前梯度蛋白2(Agr2)。
  • 晚期PBC模型和人样本中胆道黏蛋白1水平降低,分泌素治疗可增强其水平。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary biliary cholangitis (PBC) is characterised by ductopenia, ductular reaction, impairment of anion exchanger 2 (AE2) and the 'bicarbonate umbrella'. Ductulo-canalicular junction (DCJ) derangement is hypothesised to promote PBC progression. The secretin (Sct)/secretin receptor (SR) axis regulates cystic fibrosis transmembrane receptor (CFTR) and AE2, thus promoting choleresis. We evaluated the role of Sct/SR signalling on biliary secretory processes and subsequent injury in a late-stage PBC mouse model and human samples. METHODS: At 32 weeks of age, female and male wild-type and dominant-negative transforming growth factor beta receptor II (late-stage PBC model) mice were treated with Sct for 1 or 8 weeks. Bulk RNA-sequencing was performed in isolated cholangiocytes from mouse models. RESULTS: Biliary Sct/SR/CFTR/AE2 expression and bile bicarbonate levels were reduced in late-stage PBC mouse models and human samples. Sct treatment decreased bile duct loss, ductular reaction, inflammation, and fibrosis in late-stage PBC models. Sct reduced hepatic bile acid levels, modified bile acid composition, and restored the DCJ and 'bicarbonate umbrella'. RNA-sequencing identified that Sct promoted mature epithelial marker expression, specifically anterior grade protein 2 (Agr2). Late-stage PBC models and human samples exhibited reduced biliary mucin 1 levels, which were enhanced by Sct treatment. CONCLUSION: Loss of Sct/SR signalling in late-stage PBC results in a faulty 'bicarbonate umbrella' and reduced Agr2-mediated mucin production. Sct restores cholangiocyte secretory processes and DCJ formation through enhanced mature cholangiocyte phenotypes and bile duct growth. Sct treatment may be beneficial for individuals with late-stage PBC. IMPACT AND IMPLICATIONS: Secretin (Sct) regulates biliary proliferation and bicarbonate secretion in cholangiocytes via its receptor, SR, and in mouse models and human samples of late-stage primary biliary cholangitis (PBC), the Sct/SR axis is blunted along with loss of the protective 'bicarbonate umbrella'. We found that both short- and long-term Sct treatment ameliorated ductular reaction, immune cell influx, and liver fibrosis in late-stage PBC mouse models. Importantly, Sct treatment promoted bicarbonate and mucin secretion and hepatic bile acid efflux, thus reducing cholestatic and toxic bile acid-associated injury in late-stage PBC mouse models. Our work perpetuates the hypothesis that PBC pathogenesis hinges on secretory defects, and restoration of secretory processes that promote the 'bicarbonate umbrella' may be important for amelioration of PBC-associated damage.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kennedy L, Carpino G, Owen T, et al. Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes. J Hepatol. 2022. PMID: 35987275. doi:10.1016/j.jhep.2022.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。